Pre-analytical and analytical aspects along with poor interlaboratory scoring reproducibility are some of the identified causes of variability in Ki67 assessment, which has limited the international adoption in clinical breast cancer management [18, 19, 21]. This evidence concerns the gene MKI67 and breast carcinoma.